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Abstract
Introduction: Epstein-Barr virus (EBV)-associated tumors show different expression patterns of latency genes. Since in breast
carcinoma this pattern is not yet fully described, our aim was to characterize EBV latency pattern in our EBV positive breast
carcinoma series.
Methods: The study was conducted on 71 biopsies of breast carcinoma and in 48 non-neoplastic breast controls. EBNA1,
LMP2A and LMP1 expression was assessed by immunohistochemistry with monoclonal antibodies, while viral genomic DNA
and EBERs RNA transcripts expression was performed by in situ hybridization. EBV presence was confirmed by PCR.
Results: EBV genomic DNA and EBNA1 expression were detected in 31% (22/71) of patients specifically restricted to tumor
epithelial cells in breast carcinoma while all breast control samples were negative for both viral DNA and EBNA1 protein.
LMP2A was detected in 73% of EBNA1 positive cases, none of which expressed either LMP1 protein or EBERs transcripts.
Conclusions: These findings suggest that EBV expression pattern in the studied biopsies could be different from those
previously observed in breast carcinoma cell lines and lead us to suggest a new, EBNA1, LMP2A positive and LMP1 and
EBERs negative latency profile in breast carcinoma in our population.
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Introduction
Epstein-Barr virus (EBV) is a ubiquitous human c-herpes virus
(genus lymphocryptovirus) that has been linked to a variety of
lymphoid and epithelial malignancies, such as Burkitt (BL),
Hodgkin (HL) and NK/T lymphomas, nasopharyngeal (NPC)
and gastric carcinoma (GC).[1] Given that the list of EBV-related
malignancies continues to increase, the World Health Organiza-
tion classified EBV as a carcinogenic agent in 1997.[2]
All herpes viruses display two phases in their infective cycle that
together describe persistent infection; these are latency and lytic
replication.[3] In EBV-associated tumors, the virus establishes a
latent infection, which is characterized by the limited expression of
a subset of viral latent genes. The particular expression pattern of
different latent genes defines three latency programs specific to
each tumor type. Only EBV-encoded nuclear antigen 1 (EBNA1)
is essential for the persistence and replication of the viral genome
and is consistently expressed in all types of latencies.[4] EBV
associated cancers vary markedly in viral prevalence and in
patterns of latent gene expression (Table 1) suggesting that EBV
may affect cell growth in several ways.[5] Latency III pattern
express both EBERs and BARTs transcripts and all the EBV latent
proteins: the 6 nuclear antigens (EBNA1, EBNA2, EBNA3A,
EBNA3B, EBNA3C and EBNA-LP) and three membrane proteins
(LMP1, LMP2A and LMP2B), and is characteristic for lympho-
blastoid cell lines and post-transplant lymphoproliferative disease.
Latency II pattern express the EBERs, BARTs transcripts,
EBNA1 protein and the latent membrane proteins (LMP1,
LMP2A and LMP2B), and is associated to HL and NPC. Finally,
latency I is found in BL and GC and is only restricted to the
expression of both transcripts and EBNA1 protein. While B cells
have the potential to support any of these three types of latent
infection, non-B cells generally display either a Latency I or
Latency II type of infection.[6]
Breast carcinoma is among the most frequent female malig-
nancies worldwide.[7] Even though there are well-known risk
factors associated with it, they only seem to explain about half of
the cases.[8,9] As the etiology of this pathology is poorly
understood, novel routes of disease pathogenesis are to be
considered. Presently, a large number of infectious agents have
been identified which either cause or contribute to specific human
cancers, and particularly many studies have suggested that some
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cancer.[10] Several laboratories have reported EBV association in
a subset of breast tumors, while others have disclosed negative
results.[11,12,13,14,15] It has also been reported that breast
cancer cells are heterogeneous in terms of EBV genome content
and distribution and this raises the possibility that even though
EBV might have no etiological role, it can still contribute to tumor
development.[16] Moreover, it has been suggested that EBV could
confer breast cancer cells in vitro with resistance to chemothera-
peutic drugs by means of over expression of a multidrug resistance
gene.[17]
Even though EBV latency pattern is extensively characterized
in EBV-associated lymphomas, and also in NPC and GC, the
latency pattern in breast carcinoma is not yet fully described. A
better understanding of EBV expression pattern in this malig-
nancy could ultimately result in novel EBV-targeted therapy
which could be applied to patients with EBV positive tumors in
addition to conventional chemotherapy. Therefore, our aim was
to evaluate EBV latency pattern in this EBV positive breast
carcinoma series. To the best of our knowledge this is the first
work to describe EBV latency pattern, with LMP2A expression in
breast carcinoma.
Methods
Ethics statement
This study has the approval of the Institutional Review Board
and the Ethics Board of both M. Villegas de Martinez Hospital
and Ricardo Gutierrez Children Hospital and is also in
accordance with the Helsinki Declaration of 1975, as revised
in 1983. A written informed consent was obtained from every
patient after the nature of the procedure had been fully
explained.
1. Patients and samples
The study was conducted on 71 biopsies of breast carcinoma (59
patients previously reported [13]), collected without any preselec-
tion criteria from the pathological archives of the Pathology
Service of M. Villegas de Martinez Hospital. Tumors, which were
typed according to the American Joint Committee on Cancer
[18], included 7 invasive lobular carcinomas and 64 invasive
ductal carcinomas. Patients’ age ranged from 35 to 96 years
(median age, 65 years). As controls we studied 17 biopsies of
fibroadenomas, 9 of benign epithelial proliferation, 4 of atypical
ductal hyperplasia and 10 of usual ductal hyperplasia and 8
normal breast tissues of female patients.
2. PCR
DNA was extracted from tumor fixed biopsies using QIAamp
DNA Mini Kit (QIAGEN GmbH, Hilden, Germany) following
manufacturer’s instructions. PCR against EBERs DNA was
performed as previously described.[19]
3. Immunohistochemistry (IHC)
Formalin-fixed, paraffin embedded tissue sections were assayed
for EBV latent membrane protein1 (LMP1) (clone CS1-4, mouse,
Dako, Carpinteria, USA), EBV nuclear antigen1 (EBNA1) (clones
2B4 and 1H4, rat) and latent membrane protein2A (LMP2A)
(clone 4E11,rat) (all 3 clones kind gift from Dr. Elisabeth Kremmer
[19]) immunohistochemical expression with monoclonal antibod-
ies (mAb). For LMP1 mAb, antigen unmasking with citrate buffer
pH 6 in microwave oven (533 watts) for five minutes was followed
by endogenous peroxidase blockade with 3% H2O2 for 15 minutes
at room temperature. Tris-HCl 0,05 M 1% bovine albumin
pH 7.6 was used for nonspecific site blockade. Tissue sections were
incubated with a 1/50 dilution of LMP1 for 90 minutes at room
temperature. A streptavidin-biotin-peroxidase complex detection
system (LSAB, Dako, Carpinteria, USA) was used for amplifica-
tion and detection. Immunohistochemistry (IHC) for both clones
of EBNA1 and for LMP2A was performed with Tris-EDTA
10 mM/1 mM pH 9 unmasking for 5 minutes in microwave oven
(533 watts). Endogenous peroxidase was blocked and nonspecific
site blockade was performed as for LMP1 antibody. Both EBNA1
clones were incubated at a 1/50 dilution for 1 hour at room
temperature. A peroxidase-linked anti-rat antibody (Whole
molecule A5795) (Sigma, Missouri, USA) was used for amplifica-
tion and commercial DAB kit system for detection (Dako,
Carpinteria, USA).
Morover, double staining IHC with LMP2A (clone 4E11) and
cytokeratin 7 (CK7) (clone OV-TL 12/30, mouse) (Dako,
Carpinteria, USA) antibodies was performed. LMP2a was stained
as described above followed by staining with CK7. Briefly,
LMP2A stained samples were incubated for 30 minutes at room
temperature with CK7 and followed by 30 minutes incubation
with a biotinylated-anti-mouse antibody at room temperature
(Dako, Carpinteria, USA). A streptavidin-biotin-alcaline phospha-
tase complex detection system was used for amplification and
detection (Vector blue AP substrate kit III, Vector Laboratories,
Burlingame, USA).
4. EBERs In situ hybridization
EBERs RNA In situ hybridization (EBERs ISH) to detect
EBERs transcripts was performed on paraffin sections according
Table 1. EBV gene latency programs.
Latency
program EBV genes expressed Associated Malignancy
EBERs/BARTs EBNA1 LMP1 LMP2A EBNA2 EBNA3s/EBNA-LP
0 + N.D. - + - - Peripheral blood memory B cells
I ++ - - - - BL, PEL, GC
II ++ + + - - HL, NPC
III + ++ +++ IM, PTLD
Here described - + - +/2 N.D.* N.D.* Breast carcinoma
N.D.: not determined; BL: Burkitt lymphoma; PEL: Primary effusion lymphoma; PTLD: post-transplant lymphoproliferative disorders; GC: gastric carcinoma; HL: Hodgkin
lymphoma; NPC: nasopharyngeal carcinoma; IM: infectious mononucleosis.
*: not determined due to unavailability of commercial antibodies for formalin fixed, paraffin embedded tissue sections.
doi:10.1371/journal.pone.0013603.t001
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and EBERs peptide nucleic acid probe labeled with FITC,
followed by an alcaline phosfatase linked antibody anti-FITC
(Dako, Carpinteria, USA).
5. BamH1W DNA In situ hybridization
BamH1W DNA In situ hybridization (BamH1W DNA ISH) to
detect EBV DNA genome was performed with a commercial kit
according to manufacturer’s instructions using a biotin labeled
DNA probe followed by an alcaline phosfatase linked antibody
anti-biotin (PanPath, Budel, The Netherlands).
As positive control for EBNA1, LMP1, LMP2A, EBERs RNA
ISH BamH1W DNA ISH, B95.8 cells were spined down for 10
minutes at 1200 rpm. Pelleted cells were clotted with two volumes
of a 90% ethanol:40%formalin:acetic acid (80:15:5) solution
during 24 hours and then processed for histology and slides
preparation as for tissue. For LMP1 and EBERs RNA ISH we also
included an EBV positive Hodgkin lymphoma case as a positive
control.
A well characterized EBV negative Hodgkin lymphoma from
Ricardo Gutie ´rrez Children Hospital was used as negative control
in each staining procedure.
6. Statistical analysis
Statistical analysis was performed using GraphPad InStat
software, version 3.05 (Graphpad, San Diego, United States). For
the univariate analysis, Chi square test was used to assess the
association between categorical variables. All tests were two-sided,
and a P value of less than 0.05 was considered statistically significant.
Results
Twenty two out of 71 (31%) cases were EBV positive by EBERs
specific PCR. To discard the possibility that the positive signal was
given by EBV infected infiltrating B-cells within the homogenized
tissue, all samples were assayed for viral DNA genome by means of
BamH1W DNA ISH and the results matched the 22 EBV EBERs
PCR status for all the 71 cases. Nuclear staining corresponding to
EBV DNA genome positive hybridization was observed in the
nucleus of about 40% of tumor cells in each biopsy, but not in
infiltrating B-cells (Figures 1A and B). Breast non-neoplastic
controls and the HL case used as EBV negative control were all
negative for EBV genome by BamH1W DNA ISH (Figure 1C).
EBNA1 expression was analyzed by IHC and all 22 (31%) of 71
EBV DNA positive cases were found to be positive. Granular
nuclear staining was observed in tumor epithelial cells in a similar
percent as EBV genome hybridization with both clones (1H4 and
2B4), but it was absent in infiltrating B-cells (Figures 2A and C). All
non-neoplastic controls as well as the EBV negative HL were
negative for both clones of EBNA1 (Figures 2B and D). Although it
was reported that the 2B4 clone might not be completely specific
for EBV due to cross-reactivity with tumor proteins [20] all our
results with the 2B4 clone correlated exactly with the 1H4 clone
and also with PCR and EBV DNA genome hybridization results.
We then focused on EBV-positive cases by BamH1W DNA ISH to
evaluate EBV protein expression and characterize their latency
pattern. Therefore, in these cases we analyzed EBERs by EBERs
ISH, and LMP1 and LMP2A expression by IHC. LMP2A was
detected in 16 (73%) of the 22 EBV DNA positive cases. Positive
staining was observed in the cytoplasm and membrane in a
variable percentage of tumor epithelial cells but similarly to
EBNA1, it was not detected in bystander B-cells (Figure 3A). All
control samples were negative for LMP2A (Figure 3B).
To further confirm that the LMP2A expressing cells were of
epithelial lineage, we performed double staining IHC with
LMP2A mAb followed by CK7 mAb. All 16 LMP2A positive
samples displayed a double staining pattern in cytoplasm and
membrane of EBV infected epithelial neoplastic cells (Figure 3C).
None of the EBV positive carcinoma cases or non-neoplastic
control samples expressed either LMP1 by IHC or EBERs by
EBERs RNA ISH. Figure 4 shows appropriate controls for these
assays.
Statistical correlation was assessed between clinical data and
three EBV expressed antigen combinations, namely EBNA1-
LMP2A-, EBNA1+LMP2A-, EBNA1+LMP2A+. We have previ-
ously reported that the presence of EBV was not correlated with
clinical outcome. [13] In this work, clinical parameters such as
tumor histology, clinical stage, metastasis development and
estrogen and progesterone receptors were not statistically associ-
ated with any particular EBV antigen pattern (p.0,05 x
2 test).
Discussion
Since 1995, EBV has been described to be associated with a
proportion of breast carcinomas by several groups, but others
Figure 1. BamH1W DNA in situ hybridization in ductal breast carcinoma. Positive BamH1W DNA in situ hybridization restricted to nucleus of
epithelial tumor cells. A) Panoramic view of invasive tumor and necrotic focus (25X). B) EBV DNA positive tumor epithelial cells (black arrows) outside
necrotic focus (100X). C) EBV DNA negative ductal breast carcinoma (100X).
doi:10.1371/journal.pone.0013603.g001
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part due to the different techniques used to detect EBV or the
molecular target chosen (EBV-derived proteins, -RNA transcripts
or -genomic DNA). Another possibility for this discrepancy could
be based on the socio-economical background of the patients
included in previous studies. It is well established that EBV
epidemiology differs between developed and developing re-
gions.[21,22] While breast tumor biopsies from patients in
developed countries in the Northern Hemisphere appear to be
EBV negative, a similar percent of association with EBV was
described in tumor biopsies from patients in developing countries
from the Southern Hemisphere. [11,12,13,14,15,23,24].
Even though PCR is potentially sensitive, it cannot differentiate
the source of EBV genome, making it non-suitable for studying
tumors with B-lymphocyte infiltrates such as breast carcinoma. On
the other hand, both EBERs and BamH1W DNA ISH, as well as
IHC for EBV latent proteins allow for the differentiation of
positive signaling cells. In this report, detection of EBV genome
and EBV-derived antigens was achieved by these three techniques;
two of them detected EBV genome, namely EBERs PCR and
BamH1W DNA ISH, and the third one detected EBNA1 protein
expression with two different clones of monoclonal antibodies
(1H4 and 2B4). So far, this is the first report that described EBV
genome by BamH1W DNA ISH specifically restricted to breast
tumor cells. Although PCR results can be argued against, we
found a straight concordance between these and those obtained by
BamH1W DNA ISH and IHC for EBNA1. Moreover, in every
positive case, whether by BamH1W DNA ISH or IHC, the
positive signal was always restricted to tumor cells and never
observed in infiltrating lymphocytes.
EBNA1 expression in the absence of both, LMP1 and EBERs,
was previously reported in invasive tumor cells.[25] Moreover, an
EBERs negative in situ hybridization pattern within EBV positive
Hodgkin lymphoma cases was also documented. [26] Particularly,
EBNA1 expression is essential for viral episome maintenance and
replication and it is expressed in all known forms of latency. In the
present study we indeed demonstrated the expression of EBNA1 in
a subset of breast carcinoma tumor cells by IHC analysis with two
different clones of monoclonal antibodies (1H4 and 2B4). Hennard
and co-workers [20] reported EBNA1 2B4 mAb cross-reactivity
with MAGE-4, a protein expressed in various human cancers.
When they compared 2B4 immunostaining against 57B mAb,
specific for MAGE-4, in EBV-negative tumors, 3/7 EBV-negative
Hodgkin lymphomas were positive with 57B mAb but only 1/7
showed unspecific staining with 2B4 mAb. The fact that only one
HL case showed unspecific staining with 2B4 mAb even after
staining enhancement with TSA is not sufficient to conclude that
this mAb cross-reacts with cellular proteins in this lymphoma.
Besides, they used EBERs ISH as criteria for establishing EBV
presence in breast carcinoma which seems to be an EBERs RNA
negative type of tumor, so the possibility that they analyzed EBV
positive breast carcinoma cases cannot be ruled out. Finally, our
Figure 2. Immunohistochemical detection of EBNA1 (clones 1H4 and 2B4). A) Ductal breast carcinoma neoplastic nuclei show positive
staining with EBNA1 (clone 1H4) monoclonal antibody, (black arrows), but no infiltrating lymphocyte gave positive signal (400X). B) EBNA1 (clone
1H4) negative ductal carcinoma tissue (400X). C) EBNA1 (clone 2B4) positive signal in nuclei of neoplastic breast cells (400X). D) EBNA1 (clone 2B4)
negative ductal carcinoma tissue (400X).
doi:10.1371/journal.pone.0013603.g002
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staining was observed in non tumor samples which were negative
for EBV genome assessed by BamH1W DNA ISH, or in the EBV-
negative Hodgkin lymphoma case.
We found EBNA1 expression in 31% of cases which is in
agreement with 32% to 52% EBV association previously described
in several geographic locations [12,13,14,15,27,28,29] and argues
with those who oppose to this association.[23,24] Together with
EBNA1, LMP2A is expressed in several EBV-related tumors
which display latency II and latency III expression profile, such as
HL and Post-Transplant Lymphoproliferative Disorders, respec-
tively.[4,30,31] We found that LMP2A is expressed in 16 (73%) of
the 22 EBNA1 positive samples. This finding is opposed to those in
previous studies, which analyzed EBV latent gene expression
pattern in breast carcinoma and failed to detect expression of
EBNA1, LMP1 and LMP2A by IHC as well as EBER by
ISH.[23,24] Additionally, by means of double IHC staining with
LMP2A mAb and CK7 mAb we confirmed the epithelial lineage
of the EBV positive cells within the tumor.
To the best of our knowledge this is the first study that
demonstrates the expression of LMP2A restricted to tumor cells in
breast carcinoma biopsies. LMP2A was found to induce the
expression of a range of genes that are involved in cell-cycle
induction and inhibition of apoptosis, in epithelial and B-cells, by
modulating both Ras/PI3-K/Akt and b-Catenin signaling path-
ways.[32,33] It was also shown to have repressive effects on the
NF-kB pathway, and induce cell migration via interaction with
spleen tyrosine kinase (syk).[34,35] Since it seems that LMP2A has
transforming characteristics in epithelial cells, and LMP1 is not
expressed in our breast carcinoma series, LMP1 oncogenic
capacity could be replaced by LMP2A in our population.
Moreover, it can be speculated that in our LMP2A positive cases,
LMP1 expression could be down regulated by LMP2A, since it has
been reported that LMP2A expression seems to inhibit LMP1
transcription in epithelial cells.[34]
Besides LMP1, we failed to detect EBERs transcripts in all the
studied biopsies, which is consistent with previous re-
ports.[23,36,37,38] This data implies that EBERs in situ hybrid-
ization, which is considered the gold standard method to detect
EBV in EBV-associated lymphoid malignancies, is not a suitable
method to apply in breast carcinoma.
As previously mentioned, there are three EBV latency patterns
described in tumors (Table 1), but EBV latency pattern in breast
carcinoma has not been fully characterized. A latency I profile was
defined for EBV-infected breast cancer cell lines, since EBNA1
together with EBER1 and BARF0 transcripts were detected, but
not EBNA2, LMP1, LMP2A and BZLF1 transcripts.[37] Our
results showing LMP2A expression and absence of EBERs
transcripts in breast carcinoma biopsies argue against this result,
and suggest that EBV expression pattern in the studied biopsies
could be different from those observed in in vitro cultured cell lines.
Controversy regarding EBV latency pattern is not uncommon in
EBV-related carcinomas. Even though latency II is defined for
EBV-positive NPC, LMP1 expression is detected in about 70% of
all cases.[2] Latency II was also originally proposed for gastric
carcinoma [39,40] but recently, the lack of detection of LMP1 in
Figure 3. Immunohistochemical detection of LMP2A and double immunohistochemical staining for LMP2A and CK7. A) Ductal breast
carcinoma with a high number of LMP2A positive cells. Positive signal for LMP2A is restricted to the cytoplasm and membrane of tumor epithelial
cells (1000X). B) LMP2A negative ductal carcinoma tissue (1000X). C) Ductal breast carcinoma. Positive double signal for LMP2A (brown signal, dotted
arrow) and CK7 (blue signal, full arrow) restricted to the cytoplasm and membrane of the same tumor epithelial cells (1000X).
doi:10.1371/journal.pone.0013603.g003
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I.[2,41,42] It is important to define EBV protein expression and
latency profile in this disease in order to identify viral proteins
which interact with cellular factors and deregulate signaling
pathways which could at last trigger neoplastic processes.
In summary, this study reinforces EBV association with breast
carcinoma in a developing country by a new approach which
detected EBV genome specifically localized in breast tumor cells.
Furthermore, LMP2A together with EBNA1 expression in
absence of EBERs transcripts and LMP1 protein in our series
lead us to suggest this new EBV latency profile in breast carcinoma
in our population. However, the fact that EBV was detected in
only 31% of breast carcinoma biopsies indicates that EBV has no
etiological role in breast carcinoma, but it can still contribute to
tumor development as a cofactor as previously suggested for EBV
positive lymphomas.[16] Further studies, such as the detection of
mRNA for all latency genes by real-time PCR, are needed to
deeply characterize and redefine EBV latency pattern in EBV-
associated breast carcinoma in Argentinean population.
Author Contributions
Conceived and designed the experiments: MVP PAC. Performed the
experiments: MAL JL. Analyzed the data: MAL EDM HG PMV JL PG.
Contributed reagents/materials/analysis tools: EDM HG PG MVP PAC.
Wrote the paper: MAL MVP PAC.
References
1. Rickinson AB, Kieff ED (2007) Epstein-Barr virus. In: Knipe DM, Griffin DE,
Lamb RA, Martin MA, Roizman B, eds. Fields virology vol. 2 5th ed
Philadelphia: Lippincott Williams & Wilkins. pp 2655–2700.
2. Delecluse HJ, Feederle B, O’Sullivan B, Taniere P (2007) Epstein-Barr virus-
associated tumours: an update for the attention of the working pathologist. J Clin
Pathol 60(12): 1358–1364.
3. Thorley-Lawson DA, Duca KA, Shapiro M (2008) Epstein-Barr virus: a
paradigm for persistent infection – for real and virtual reality. Trends Immunol
29(4): 195–201.
4. Young LS, Rickinson AB (2004) Epstein-Barr virus: 40 years on. Nat Rev
Cancer 4(10): 757–768.
5. Ku ¨ppers R (2003) B cells under influence: transformation of B cells by Epstein–
Barr virus. Nat Rev Immunol 3(10): 801–812.
6. Rowe M, Kelly GL, Bell AI, Rickinson AB (2009) Burkitt’s lymphoma: The
rosetta stone deciphering Epstein-Barr virus biology. Semin Cancer Biol 19(6):
377–388.
7. Ries LAG, Eisner M, Kosary C (2002) Cancer Statistics Review. Bethesda:
National Cancer Institute. pp 1973–1999.
8. Martin AM, Weber BL (2000) Genetic and hormonal risk factors in breast
cancer. J Natl Cancer Inst 92(14): 1126–1135.
9. Madigan MP, Ziegler RG, Benichou J (1995) Proportion of breast cancer cases
in the United States explained by well-established risk factors. J Natl Cancer Inst
87(22): 1681–1685.
10. zur Hausen H (2009) The search for infectious causes of human cancers: where
and why. Virology 392(1): 1–10.
11. Glaser SL, Hsu JL, Gulley M L (2004) Epstein-Barr Virus and breast Cancer:
State of the Evidence for Viral Carcinogenesis. Cancer Epidemiology
Biomarkers & Prevention 13(5): 688–695.
12. Ribeiro-Silva A, Ramalho LN, Garcia SB, Zucoloto S (2004) Does the
correlation between EBNA-1 and p63 expression in breast carcinomas provide a
clue to tumorigenesis in Epstein-Barr virus-related breast malignancies?
Braz J Med Biol Res 37(1): 89–95.
Figure 4. Immunohistochemical controls for LMP1 and EBERs RNA in situ hybridization. A) HL case: LMP1 positive staining in the
membrane of Reed Stenberg cells and HL mononuclear cell (400X). B) LMP1 negative ductal breast carcinoma (400X). C) EBERs RNA positive staining
in HL Reed Stenberg cells (400X). D) EBERs RNA negative ductal breast carcinoma (400X).
doi:10.1371/journal.pone.0013603.g004
EBV Latency in Breast Tumors
PLoS ONE | www.plosone.org 6 October 2010 | Volume 5 | Issue 10 | e1360313. Preciado MV, Chabay PA, De Matteo E, Gonzalez P, Grinstein S, et al. (2005)
Epstein-Barr Virus in Breast Carcinoma in Argentina. Arch Pathol Lab Med
129(3): 337–381.
14. Fawzy S, Sallam M, Awad NM (2008) Detection of Epstein-Barr virus in breast
carcinoma in Egyptian women. Clin Biochem 41(7-8): 486–492.
15. Joshi D, Quadri M, Gangane N, Joshi R, Gangane N (2009) Association of
Epstein Barr virus infection (EBV) with breast cancer in rural Indian women.
PLoS One 4(12): e8180.
16. Butel JS (2000) Viral carcinogenesis: revelation of molecular mechanisms and
etiology of human disease. Carcinogenesis 21(3): 405–426.
17. Arbach H, Viglasky V, Lefeu F, Guinebretiere JM, Ramirez V, et al. (2006)
Epstein-Barr Virus (EBV) Genome and Expression in Breast Cancer Tissue:
Effect of EBV Infection of Breast Cancer Cells on Resistance to Paclitaxel
(Taxol). J Virol 80(2): 845–853.
18. American Joint Committee on Cancer (2007) Cancer Staging Manual.
Philadelphia: Lippincott-Raven press.
19. Bonnet M, Guinebretiere JM, Kremmer E, Grunewald V, Benhamou E, et al.
(1999) Detection of Epstein-Barr virus in invasive breast cancers. J Natl Cancer
Inst 91(16): 1376–1381.
20. Hennard C, Pfuhl T, Buettner M, Becker KF, Knofel T, et al. (2006) The
antibody 2B4 directed against the Epstein–Barr virus (EBV)-encoded nuclear
antigen 1 (EBNA1) detects MAGE-4: implications for studies on the EBV
association of human cancers. J Pathol 209(4): 430–435.
21. Chan KH, Tam JSL, Peiris JSM, Seto WH, Ng MH (2001) Epstein-Barr virus
(EBV) infection in infancy. J Clin Virol 21(1): 57–62.
22. Cohen JI (2000) Epstein-Barr virus infection. N Engl J Med 343(7): 481–492.
23. Deshpande CG, Badve S, Kidwai N, Longnecker R (2002) Lack of expression of
the Epstein-Barr Virus (EBV) gene products, EBERs, EBNA1, LMP1, and
LMP2A, in breast cancer cells. Lab Invest 82(9): 1193–1199.
24. Herrmann K, Niedobitek G (2003) Lack of evidence for an association of
Epstein-Barr virus infection with breast carcinoma. Breast Cancer Res 5(1):
13–17.
25. Chu PG, Chang KL, Chen YY, Chen WG, Weiss LM (2001) No significant
association of Epstein Barr virus infection with invasive breast carcinoma.
Am J Pathol 159(4): 571–578.
26. Gan YJ, Razzouk BI, Su T, Sixbey JW (2002) A Defective, Rearranged Epstein-
Barr Virus Genome in EBER-Negative and EBER-Positive Hodgkin’s Disease.
Am J Pathol 160(3): 781–786.
27. Brink AATP, van den Brule AJC, van Diest P, Meijer CJLM (2000) Re:
Detection of Epstein-Barr virus in invasive breast cancers. J Natl cancer Inst
92(8): 655–656.
28. Grinstein S, Preciado MV, Gattuso P, Chabay P, Warren WH, et al. (2002)
Demonstration of Epstein-Barr virus in carcinomas of various sites. Cancer Res
62(17): 4876–4878.
29. Murray PG, Lissauer D, Junying J, Davies G, Moore S, et al. (2003) Reactivity
with a monoclonal antibody to Epstein-Barr virus (EBV) nuclear antigen 1
defines a subset of aggressive breast cancers in the absence of the EBV genome.
Cancer Res 63(9): 2338–2343.
30. Longnecker R (1998) Molecular biology of Epstein-Barr virus. In: McCance DJ,
ed. Human tumor viruses. Washington: American Society for Microbiology. pp
135–174.
31. Thorley-Lawson DA, Gross A (2004) Persistence of the Epstein-Barr virus and
the origins of associated lymphomas. N Engl J Med 350: 1328–1337.
32. Morrison JA, Klingelhutz AJ, Raab-Traub N (2003) Epstein-Barr Virus Latent
Membrane Protein 2A Activates B-Catenin Signaling in Epithelial Cells. J Virol
77(22): 12276–12284.
33. Fukuda M, Longnecker R (2007) Epstein-Barr Virus Latent Membrane Protein
2A Mediates Transformation through Constitutive Activation of the Ras/PI3-
K/Akt Pathway. J Virol 81(17): 9299–9306.
34. Stewart S, Dawson CW, Takada K, Curnow J, Moody CA, et al. (2004)
Epstein–Barr virus-encoded LMP2A regulates viral and cellular gene expression
by modulation of the NF-kB transcription factor pathway. Proc Natl Acad
Sci U S A 101(44): 15730–15735.
35. Lu J, Lin WH, Chen SY, Longnecker R, Tsai SC, et al. (2006) Sky tyrosine
kinase mediates Epstein-Barr virus latent membrane protein 2A-induced cell
migration in epithelial cells. J B C 281(13): 8806–8814.
36. Lespagnard L, Cochaux P, Larsimont D, Degeyter M, Velu T, et al. (1995)
Absence of Epstein-Barr virus in medullary carcinoma of the breast as
demonstrated by immunophenotyping, in situ hybridization and polymerase
chain reaction. Am J Clin Pathol 103(4): 449–455.
37. Lin JH, Tsai CH, Chu JS, Chen JY, Takada K, et al. (2007) Dysregulation of
HER2/HER3 Signaling Axis in Epstein-Barr Virus-Infected Breast Carcinoma
Cells. J Virol 81(11): 5705–5713.
38. Xue SA, Lampert IA, Haldane JS, Bridger JE, Griffin BE (2003) Epstein-Barr
virus gene expression in human breast cancer: protagonist or passenger?
Br J Cancer 89(1): 113–119.
39. Imai S, Koizumi S, Sugiera M, Tokunaga M, Uemura Y, et al. (1994) Gastric
carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus
latent infection protein. Proc Natl Acad Sci U S A 91(19): 9131–9135.
40. Sugiura M, Imai S, Tokunaga M, Koizumi S, Uchizawa M, et al. (1996)
Transcriptional analysis of Epstein-Barr virus gene expression in EBVpositive
gastric carcinoma: unique viral latency in the tumour cells. Br J Cancer 74(4):
625–631.
41. zur Hausen A, Brink A, Craanen M, Middeldorp JM, Meijer CJ, et al. (2000)
Unique transcription pattern of Epstein-Barr virus in EBV-carrying gastric
adenocarcinomas: Expression of the transforming BARF1 gene. J Cancer Res
60(10): 2745–2748.
42. Uozaki H, Fukayama M (2008) Epstein-Barr virus and gastric carcinoma – viral
carcinogenesis through epigenetic mechanisms. Int J Clin Exp Pathol 1(3):
198–216.
EBV Latency in Breast Tumors
PLoS ONE | www.plosone.org 7 October 2010 | Volume 5 | Issue 10 | e13603